SG11201907211TA - Anti-pd-l1 antibody treatment of bladder cancer - Google Patents
Anti-pd-l1 antibody treatment of bladder cancerInfo
- Publication number
- SG11201907211TA SG11201907211TA SG11201907211TA SG11201907211TA SG11201907211TA SG 11201907211T A SG11201907211T A SG 11201907211TA SG 11201907211T A SG11201907211T A SG 11201907211TA SG 11201907211T A SG11201907211T A SG 11201907211TA SG 11201907211T A SG11201907211T A SG 11201907211TA
- Authority
- SG
- Singapore
- Prior art keywords
- medimmune
- llc
- gaithersburg
- way
- bladder cancer
- Prior art date
Links
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 title abstract 9
- 206010005003 Bladder cancer Diseases 0.000 title abstract 8
- 201000005112 urinary bladder cancer Diseases 0.000 title abstract 8
- 238000011282 treatment Methods 0.000 title abstract 5
- 238000000034 method Methods 0.000 abstract 3
- 238000002560 therapeutic procedure Methods 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 229950009791 durvalumab Drugs 0.000 abstract 1
- 238000009093 first-line therapy Methods 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000002955 immunomodulating agent Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 229910052697 platinum Inorganic materials 0.000 abstract 1
- 206010044412 transitional cell carcinoma Diseases 0.000 abstract 1
- 238000011269 treatment regimen Methods 0.000 abstract 1
- 229950007217 tremelimumab Drugs 0.000 abstract 1
- 208000023747 urothelial carcinoma Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762459700P | 2017-02-16 | 2017-02-16 | |
| PCT/US2018/018513 WO2018152415A1 (en) | 2017-02-16 | 2018-02-16 | Anti-pd-l1 antibody treatment of bladder cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201907211TA true SG11201907211TA (en) | 2019-09-27 |
Family
ID=63169615
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201907211TA SG11201907211TA (en) | 2017-02-16 | 2018-02-16 | Anti-pd-l1 antibody treatment of bladder cancer |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20190359715A1 (ja) |
| EP (1) | EP3582805A4 (ja) |
| JP (2) | JP2020507596A (ja) |
| KR (2) | KR20190117014A (ja) |
| CN (2) | CN118001389A (ja) |
| AU (1) | AU2018221822A1 (ja) |
| CA (1) | CA3052652A1 (ja) |
| EA (1) | EA201991870A1 (ja) |
| IL (2) | IL302777A (ja) |
| MA (1) | MA47509A (ja) |
| SG (1) | SG11201907211TA (ja) |
| WO (1) | WO2018152415A1 (ja) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2702332C2 (ru) * | 2014-05-13 | 2019-10-08 | Медиммьюн Лимитед | Антитела к в7-н1 и к ctla-4 для лечения немелкоклеточного рака легкого |
| NZ759442A (en) | 2017-06-01 | 2024-07-05 | Cytomx Therapeutics Inc | Activatable anti-pdl1 antibodies, and methods of use thereof |
| JP2023526400A (ja) * | 2020-05-21 | 2023-06-21 | アストラゼネカ・アクチエボラーグ | 局所進行性又は転移性尿路上皮がんにおける免疫療法に対する感受性に関連する遺伝子変異量 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7947261B2 (en) * | 2003-05-23 | 2011-05-24 | Nektar Therapeutics | Conjugates formed from polymer derivatives having particular atom arrangements |
| RU2702332C2 (ru) * | 2014-05-13 | 2019-10-08 | Медиммьюн Лимитед | Антитела к в7-н1 и к ctla-4 для лечения немелкоклеточного рака легкого |
| ES2789500T5 (es) * | 2015-05-29 | 2023-09-20 | Hoffmann La Roche | Procedimientos terapéuticos y de diagnóstico para el cáncer |
| US20180364240A1 (en) * | 2015-12-10 | 2018-12-20 | Medimmune, Llc | Methods for treatment and selection of patients responsive to immune mediated cancer therapy |
| SG11201807474SA (en) * | 2016-04-25 | 2018-11-29 | Medimmune Llc | Compositions comprising coformulation of anti-pd-l1 and anti-ctla-4 antibodies |
-
2018
- 2018-02-16 MA MA047509A patent/MA47509A/fr unknown
- 2018-02-16 KR KR1020197026803A patent/KR20190117014A/ko not_active Application Discontinuation
- 2018-02-16 EA EA201991870A patent/EA201991870A1/ru unknown
- 2018-02-16 SG SG11201907211TA patent/SG11201907211TA/en unknown
- 2018-02-16 JP JP2019543851A patent/JP2020507596A/ja active Pending
- 2018-02-16 CN CN202410133870.XA patent/CN118001389A/zh active Pending
- 2018-02-16 WO PCT/US2018/018513 patent/WO2018152415A1/en unknown
- 2018-02-16 EP EP18753778.2A patent/EP3582805A4/en active Pending
- 2018-02-16 KR KR1020237034594A patent/KR20230145547A/ko not_active Application Discontinuation
- 2018-02-16 AU AU2018221822A patent/AU2018221822A1/en active Pending
- 2018-02-16 CN CN201880011428.2A patent/CN110290803A/zh active Pending
- 2018-02-16 CA CA3052652A patent/CA3052652A1/en active Pending
- 2018-02-16 US US16/486,222 patent/US20190359715A1/en not_active Abandoned
- 2018-02-16 IL IL302777A patent/IL302777A/en unknown
-
2019
- 2019-08-04 IL IL268460A patent/IL268460A/en unknown
-
2022
- 2022-04-14 US US17/720,903 patent/US20220332828A1/en active Pending
-
2023
- 2023-12-22 JP JP2023216425A patent/JP2024038034A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3582805A1 (en) | 2019-12-25 |
| CN118001389A (zh) | 2024-05-10 |
| KR20230145547A (ko) | 2023-10-17 |
| EP3582805A4 (en) | 2021-03-10 |
| AU2018221822A1 (en) | 2019-09-26 |
| IL268460A (en) | 2019-09-26 |
| EA201991870A1 (ru) | 2020-02-12 |
| JP2020507596A (ja) | 2020-03-12 |
| WO2018152415A1 (en) | 2018-08-23 |
| KR20190117014A (ko) | 2019-10-15 |
| CN110290803A (zh) | 2019-09-27 |
| US20220332828A1 (en) | 2022-10-20 |
| MA47509A (fr) | 2019-12-25 |
| JP2024038034A (ja) | 2024-03-19 |
| CA3052652A1 (en) | 2018-08-23 |
| IL302777A (en) | 2023-07-01 |
| US20190359715A1 (en) | 2019-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201903021WA (en) | Anti-human 4-1 bb antibodies and use thereof | |
| SG11201804839WA (en) | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
| SG11201803956UA (en) | Anti-dr5 antibodies and methods of use thereof | |
| SG11201809089QA (en) | Bispecific binding proteins and uses thereof | |
| SG11201900677SA (en) | Combination therapies of chimeric antigen receptors adn pd-1 inhibitors | |
| SG11201909572QA (en) | Methods for the treatment of subjects having a hepatitis b virus (hbv) infection | |
| SG11201807176XA (en) | TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF | |
| SG11201907891XA (en) | Combination therapy for the treatment or prevention of tumours | |
| SG11201906297QA (en) | Nucleic acids encoding crispr-associated proteins and uses thereof | |
| SG11201900344YA (en) | Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor | |
| SG11201903454VA (en) | Immunologically discernible cell surface variants for use in cell therapy | |
| SG11201806340YA (en) | Zika virus vaccine | |
| SG11201810023QA (en) | Anti-tim-3 antibodies and methods of use thereof | |
| SG11201906192SA (en) | Methods of treating cancer with anti-pd-1 antibodies | |
| SG11201811292RA (en) | Compositions and methods for the depletion of cells | |
| SG11201809764XA (en) | Humanized anti-il-1r3 antibodies | |
| SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
| SG11201907211TA (en) | Anti-pd-l1 antibody treatment of bladder cancer | |
| SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| SG11201806419RA (en) | Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates | |
| SG11201901961SA (en) | Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x | |
| SG11201809100QA (en) | Use of gram negative species to treat atopic dermatitis | |
| SG11201909064RA (en) | Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer | |
| SG11201901762WA (en) | Methods and composition for the prediction of the activity of enzastaurin | |
| SG11201810371XA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF |